Join
Live feed
·
PRReleasevia Quantisnow
Vera Therapeutics Inc. logo

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

ByQuantisnow·Wall Street's wire, on your screen.
VERA· Vera Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VERA (Vera Therapeutics Inc.) and more on Quantisnow.